# Ming‐Sound Tsao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ming-sound-tsao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 113,355 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 148 |
| i10-index | 658 |
| Last Known Institution | University Health Network |
| OpenAlex ID | https://openalex.org/A5073362806 |
| ORCID iD | https://orcid.org/0000-0002-9160-5405 |
| Works | 1,584 |

## Researcher papers

Showing 12 of 33.

- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-tnm-stage/)
- [The landscape of somatic copy-number alteration across human cancers](https://scholariq.org/papers/the-landscape-of-somatic-copy-number-alteration-across-human-cancers/)
- [Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes](https://scholariq.org/papers/pancreatic-cancer-genomes-reveal-aberrations-in-axon-guidance-pathway-genes/)
- [Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome](https://scholariq.org/papers/erlotinib-in-lung-cancer-molecular-and-clinical-predictors-of-outcome/)
- [Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer](https://scholariq.org/papers/vinorelbine-plus-cisplatin-vs-observation-in-resected-non-small-cell-lung-cancer/)
- [PD-L1 as a biomarker of response to immune-checkpoint inhibitors](https://scholariq.org/papers/pd-l1-as-a-biomarker-of-response-to-immune-checkpoint-inhibitors/)
- [The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015](https://scholariq.org/papers/the-2021-who-classification-of-lung-tumors-impact-of-advances-since-2015/)
- [SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas](https://scholariq.org/papers/sox2-is-an-amplified-lineage-survival-oncogene-in-lung-and-esophageal-squamous/)
- [Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology](https://scholariq.org/papers/updated-molecular-testing-guideline-for-the-selection-of-lung-cancer-patients/)
- [PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project](https://scholariq.org/papers/pd-l1-immunohistochemistry-comparability-study-in-real-life-clinical-samples/)
- [Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes](https://scholariq.org/papers/large-scale-association-analysis-identifies-new-lung-cancer-susceptibility-loci/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [University Health Network](https://scholariq.org/institutions/university-health-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.